ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentEpalingesCombioxin SA
Combioxin SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Combioxin SA is the development of life-saving medications for severe infections, particularly for the treatment of severe bacterial pneumonias. The company focuses on the development of innovative therapeutics, such as CAL02, a first-in-class anti-toxin agent used to neutralize virulence factors that play a crucial role in the development of organ failure and fatal complications in severe infections.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Combioxin SA

✓ Offered2
Antivirulence drug (CAL02)
CAL02, a broad-acting, first-in-class antivirulence active ingredient in development for the treatment of severe community-acquired bacterial pneumonia; with proprietary liposomes for neutralising bacterial toxins.
Therapy for acquired immunodeficiency in critically ill patients
Therapeutic approach in development for the treatment of acquired immunodeficiency in the intensive care unit, with restoration of immune function and immune balance as an add-on therapy.
Trust & reputation

ranQ Trust Score of Combioxin SA: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Combioxin SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Combioxin SA scores 84.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.89.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Combioxin SA scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Combioxin SA scores 23.1 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.22.94%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.23.34%
Qualifications+0.00

Combioxin SA reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

June 30, 2026Media
Three Swiss biotech companies secure grants
startupticker.ch

Knowledge

No knowledge articles yet

Once Combioxin SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Combioxin SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Combioxin SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Combioxin SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Route de la Corniche 8
1066 Epalinges

At a glance

Legal form
Corporation
UID
CHE-310.572.972
Founded
2015 · 11 years
Last commercial register change
June 15, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    OB
    Opna Bio Switzerland Sàrl
    Epalinges
    AG
    Alithea Genomics SA
    Epalinges
    AT
    ADC Therapeutics SA
    Epalinges
    NB
    ND BioSciences SA
    Epalinges
    NS
    Novassay SA
    Epalinges
    ST
    Synameta Therapeutics SARL
    Epalinges
    ES
    Exciva Switzerland SA
    Epalinges
    NS
    NewBiologix SA
    Epalinges